{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:19Z","timestamp":1792723099544,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ajt.2026.09.039","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:19:31Z","timestamp":1790723971000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes after living donor liver transplant for intrahepatic cholangiocarcinoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-9811","authenticated-orcid":false,"given":"Vrishketan","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0974-7904","authenticated-orcid":false,"given":"Vikraman","family":"Gunabushanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-9775","authenticated-orcid":false,"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3619-2804","authenticated-orcid":false,"given":"Soumik","family":"Purkayastha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-3150","authenticated-orcid":false,"given":"Elissa","family":"Bardhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-1068","authenticated-orcid":false,"given":"David","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6841-7913","authenticated-orcid":false,"given":"Swaytha","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7256-3819","authenticated-orcid":false,"given":"Christopher","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-1000","authenticated-orcid":false,"given":"Abhinav","family":"Humar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajt.2026.09.039_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.14701\/ahbps.21-173","article-title":"Changing incidence and survival of intrahepatic cholangiocarcinoma based on Surveillance, Epidemiology, and End Results database (2000-2017)","volume":"26","author":"Ali","year":"2022","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"9","key":"10.1016\/j.ajt.2026.09.039_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ajt.2026.09.039_bib3","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajt.2026.09.039_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104923","article-title":"Is it a new era for intrahepatic cholangiocarcinoma?","volume":"215","author":"Liguori","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.ajt.2026.09.039_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.hpb.2023.06.019","article-title":"Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma","volume":"25","author":"Olthof","year":"2023","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ajt.2026.09.039_bib6","article-title":"Gemcitabine cisplatin and durvalumab experience in advanced biliary tract cancers: a real-world, multicentric data from India","volume":"10","author":"Muddu","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"10.1016\/j.ajt.2026.09.039_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2026.09.039_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf054","article-title":"Liver transplantation for locally advanced non-resectable intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: early results from the TESLA trial","volume":"112","author":"Yaqub","year":"2025","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.ajt.2026.09.039_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ajt.2026.09.039_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.3112","article-title":"Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant","volume":"156","author":"Lai","year":"2021","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.ajt.2026.09.039_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/SLA.0000000000003463","article-title":"Adult living donor versus deceased donor liver transplant (LDLT versus DDLT) at a single center: time to change our paradigm for liver transplant","volume":"270","author":"Humar","year":"2019","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ajt.2026.09.039_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/hbsn.2017.01.16","article-title":"Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?","volume":"6","author":"Koay","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"10.1016\/j.ajt.2026.09.039_bib14","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1097\/SLA.0000000000005749","article-title":"Textbook outcomes after open live donor right hepatectomy and open right hepatic lobectomy for cancer in 686 patients: redefining the benchmark","volume":"278","author":"Dogeas","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.ajt.2026.09.039_bib15","series-title":"UPMC Oncomine Comprehensive Assay","year":"2025"},{"issue":"4","key":"10.1016\/j.ajt.2026.09.039_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.14701\/ahbps.2017.21.4.205","article-title":"Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors","volume":"21","author":"Thorat","year":"2017","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"6","key":"10.1016\/j.ajt.2026.09.039_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ajt.14623","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study","volume":"18","author":"Jeng","year":"2018","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2026.09.039_bib18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ajt.2026.09.039_bib19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.29219","article-title":"Development of a novel frailty index to predict mortality in patients with end-stage liver disease","volume":"66","author":"Lai","year":"2017","journal-title":"Hepatology"},{"issue":"9935","key":"10.1016\/j.ajt.2026.09.039_bib20","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajt.2026.09.039_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"2S1","key":"10.1016\/j.ajt.2026.09.039_bib22","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.ajt.2025.01.022","article-title":"OPTN\/SRTR 2023 annual data report: liver","volume":"25","author":"Kwong","year":"2025","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2026.09.039_bib23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.cgh.2017.11.045","article-title":"Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States","volume":"16","author":"Cholankeril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ajt.2026.09.039_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jama.2024.21503","article-title":"Trends in hospitalizations and liver transplants associated with alcohol-induced liver disease","volume":"333","author":"Sethi","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ajt.2026.09.039_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ajt.2026.09.039_bib26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1600-6143.2009.02557.x","article-title":"Unique early gene expression patterns in human adult-to-adult living donor liver grafts compared to deceased donor grafts","volume":"9","author":"de Jonge","year":"2009","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2026.09.039_bib27","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.transproceed.2020.02.050","article-title":"Impact of extended-criteria donor liver grafts on benchmark metrics of clinical outcome after liver transplantation: a single center experience","volume":"52","author":"Pagano","year":"2020","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.ajt.2026.09.039_bib28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ajt.2026.09.039_bib29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2010.12.040","article-title":"The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma","volume":"55","author":"Merani","year":"2011","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajt.2026.09.039_bib30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1186\/s12967-024-05854-9","article-title":"Multi-omics-driven discovery of invasive patterns and treatment strategies in CA19-9 positive intrahepatic cholangiocarcinoma","volume":"22","author":"Ma","year":"2024","journal-title":"J Transl Med"},{"issue":"12","key":"10.1016\/j.ajt.2026.09.039_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","article-title":"Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients","volume":"147","author":"Ribero","year":"2012","journal-title":"Arch Surg"},{"issue":"10","key":"10.1016\/j.ajt.2026.09.039_bib32","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/BF01536670","article-title":"Elevated serum levels of tumor marker CA19-9 in acute cholangitis","volume":"33","author":"Albert","year":"1988","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.ajt.2026.09.039_bib33","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.21873\/anticanres.12931","article-title":"Relationship between CA 19.9 and the Lewis phenotype: options to improve diagnostic efficiency","volume":"38","author":"Parra-Robert","year":"2018","journal-title":"Anticancer Res"},{"issue":"10458","key":"10.1016\/j.ajt.2026.09.039_bib34","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526028017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526028017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:54:42Z","timestamp":1792720482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613526028017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S1600613526028017"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2026.09.039","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes after living donor liver transplant for intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2026.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}